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Abstract
The E3 ligase parkin ubiquitinates outer mitochondrial membrane
proteins during oxidative stress and is linked to early-onset
Parkinson’s disease. Parkin is autoinhibited but is activated by the
kinase PINK1 that phosphorylates ubiquitin leading to parkin
recruitment, and stimulates phosphorylation of parkin’s N-term-
inal ubiquitin-like (pUbl) domain. How these events alter the
structure of parkin to allow recruitment of an E2~Ub conjugate
and enhanced ubiquitination is an unresolved question. We
present a model of an E2~Ub conjugate bound to the phospho-
ubiquitin-loaded C-terminus of parkin, derived from NMR chemical
shift perturbation experiments. We show the UbcH7~Ub conjugate
binds in the open state whereby conjugated ubiquitin binds to the
RING1/IBR interface. Further, NMR and mass spectrometry experi-
ments indicate the RING0/RING2 interface is re-modelled,
remote from the E2 binding site, and this alters the reactivity of
the RING2(Rcat) catalytic cysteine, needed for ubiquitin transfer.
Our experiments provide evidence that parkin phosphorylation
and E2~Ub recruitment act synergistically to enhance a weak
interaction of the pUbl domain with the RING0 domain and rear-
range the location of the RING2(Rcat) domain to drive parkin
activity.
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Introduction
Parkinson’s disease is the second most common neurodegenerative
disease estimated to affect 1% of the population over 60 years of
age (Tysnes & Storstein, 2017). The disease is believed to be a result
of genetic predisposition or environmental factors (Corrigan et al,
1998) that lead to oxidative damage of mitochondrial proteins
(Alam et al, 1997) and subsequent mitochondrial dysfunction
(Schapira et al, 1990) and is characterized in patients by the loss of
dopaminergic neurons in the substantia nigra of the midbrain
(Hornykiewicz, 1966; Riederer & Wuketich, 1976). In addition to
sporadic Parkinson’s disease, there are also genetic forms of the
disease that account for approximately 10% of all cases. In particu-
lar, mutations in the genes for PARK2 and PARK6 give rise to early-
onset or autosomal recessive juvenile parkinsonism (ARJP) forms of
the disease that have similar symptoms including rigidity, bradyki-
nesia and postural instability (Jankovic, 2008) but affect individuals
at a much younger age. PARK2 encodes the E3 ubiquitin ligase
parkin (Kitada et al, 1998) where mutations account for 50% of all
ARJP cases. Along with the PTEN-induced kinase (PINK1) trans-
lated from PARK6, these proteins use the ubiquitin degradation
pathway to turnover damaged mitochondria and maintain mito-
chondrial homeostasis, especially under conditions of oxidative
stress.
Parkin is a member of the RBR E3 ligase family that also includes
the human homolog of Ariadne (HHARI) and HOIL-1 interacting
protein (HOIP; Spratt et al, 2014). These enzymes have a character-
istic RBR motif comprising RING1, in-Between-RING and RING2
(Rcat) domains that distinguish them from HECT and RING classes
of E3 enzymes in terms of structure, mechanism and functionality.
In particular, RBR E3 ligases incorporate a hybrid ubiquitination
mechanism (Wenzel et al, 2011) whereby an E2 conjugating
enzyme is recruited to the RING1 domain (similar to RING E3
ligases) and ubiquitin (Ub) is transferred from the E2~Ub conjugate
to a catalytic cysteine in the RING2(Rcat) domain (similar to HECT
E3 mechanisms) prior to labelling of a substrate lysine. RBR E3
ligases and RING E3 ligases have RING domains that are structurally
similar and are expected to recruit E2 enzymes in a similar fashion
(Budhidarmo et al, 2012), as recently shown in crystal structures of
the RBR E3 ligases HHARI with UbcH7-Ub (Dove et al, 2017; Yuan
et al, 2017) and HOIP with UbcH5b-Ub (Lechtenberg et al, 2016).
However, a distinguishing feature of the HHARI and HOIP RBR E3
ligases is their ability to recognize an extended (“open”) form of the
E2~Ub conjugate similar to that used by HECT E3 enzymes. This
E2~Ub arrangement promotes a conformation susceptible to the
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transthiolation reaction needed to transfer the Ub cargo from the E2
enzyme to the catalytic cysteine of the RING2(Rcat) domain. Parkin
on the other hand has been shown to function with a variety of E2
enzymes including UbcH7 and UbcH5b (Chaugule et al, 2011;
Wenzel et al, 2011) although it appears that UbcH7 is the optimal
E2 enzyme owing to its preference for ubiquitin transfer to cysteine,
a requirement for RBR E3 ligases. While the conformation of the
UbcH7~Ub conjugate during recruitment by parkin is unknown, it
has been established that a cryptic Ub binding site within the
RING1–IBR interface is only uncovered upon pUb binding to parkin
and this has been proposed to help coordinate E2~Ub recruitment
(Kumar et al, 2017).
All RBR E3 ligases identified to date, including parkin, appear to
be uniquely regulated (Spratt et al, 2014; Walden & Rittinger, 2018).
Parkin is normally autoinhibited by an accessory ubiquitin-like
(Ubl) domain (Chaugule et al, 2011) that blocks both the E2 and
cryptic ubiquitin sites. In addition, structures show that another
accessory module, the RING0 domain, partially obscures the cata-
lytic cysteine in the RING2(Rcat) domain protecting this site from
Ub transfer. At least two steps have been identified for the activation
of parkin both as a result of phosphorylation by PINK1. Under
oxidative stress conditions, PINK1 is activated and phosphorylates
ubiquitin (pUb) near the outer mitochondrial membrane. This in
turn helps recruit parkin to the membrane through binding of pUb
to the RING1–IBR region of the E3 ligase (Sauve´ et al, 2015; Wauer
et al, 2015; Kumar et al, 2017) and subsequent phosphorylation of
parkin’s Ubl (pUbl) domain (Ordureau et al, 2014). These two
events greatly stimulate ubiquitination activity (Kondapalli et al,
2012; Shiba-Fukushima et al, 2012; Kane et al, 2014; Kazlauskaite
et al, 2014; Koyano et al, 2014) through an allosteric displacement
mechanism of the pUbl domain from parkin (Kumar et al, 2015;
Sauve´ et al, 2015). What is less clear is how parkin positions the
E2~Ub conjugate to enable transfer of the Ub molecule to the RING2
(Rcat) domain as a necessary step for catalysis. Current crystal
structures of parkin show the proposed E2 binding site on the
RING1 domain is > 50 A˚ from the catalytic site (C431) in the RING2
(Rcat) domain suggesting a significant conformational rearrange-
ment is needed (Riley et al, 2013; Trempe et al, 2013; Wauer &
Komander, 2013; Kumar et al, 2015, 2017; Sauve´ et al, 2015; Wauer
et al, 2015). A similar dilemma arises from recent structures of
HHARI in complex with UbcH7-Ub that show the ubiquitin molecule
is 47–53 A˚ from the catalytic site (Dove et al, 2017; Yuan et al,
2017). Alternatively, structures of HOIP:E2-Ub and parkin:pUb
complexes assembled from domain-swapping or symmetry-related
molecules raise the possibility of co-operation between multiple E3
ligase molecules to promote ubiquitin transfer (Lechtenberg et al,
2016; Kumar et al, 2017).
In this work, we identify how the pUbl domain and E2~Ub conju-
gate co-operate to regulate parkin activity. We use NMR spec-
troscopy and chemical shift perturbation experiments to determine a
model of pUb-bound parkin in complex with its biological
UbcH7~Ub conjugate. The structure shows that a non-hydrolysable
UbcH7-Ub conjugate binds in an altered “open” conformation with
its thioester linkage poised for Ub transfer to the catalytic cysteine
of the RING2(Rcat) domain. We show that E2-Ub recruitment to
parkin results in two distinct types of NMR chemical shift changes:
one set that is consistent with the E2~Ub binding site and a second
set that corresponds to residues near the RING0/RING2 interface,
indicating this region is re-modelled during E2~Ub recruitment. We
show that the reactivity of the catalytic cysteine (C431) in the
RING2(Rcat) domain is sensitive to both parkin phosphorylation
and E2-Ub binding. Further, we use NMR spectroscopy and hydro-
gen–deuterium exchange (HDX) mass spectrometry experiments to
show that the pUbl domain undergoes transient interaction with the
RING0 domain that is enhanced upon E2~Ub recruitment by parkin.
These events also result in large changes in the exposure of the
RING2(Rcat) domain consistent with its rearrangement. Overall, our
work provides a dynamic picture of parkin activation whereby
PINK1 phosphorylation of parkin and E2~Ub recruitment co-operate
to drive parkin activity.
Results
Dual phosphorylation leads to dynamic repositioning of the
pUbl domain
Multiple high-resolution structures of parkin have provided signifi-
cant insights into its E3 ligase function. Structures of near full-length
parkin (Kumar et al, 2015; Sauve´ et al, 2015) show the C-terminal
RING0–RING1–IBR–RING2(Rcat) domains (termed “R0RBR”) form a
compact unit whereby the N-terminal Ubl domain interacts with the
RING1 and IBR domains and portions of the tether region (Fig 1A).
This mode of interaction confirmed that the Ubl domain exerted its
previously identified autoinhibitory effect (Chaugule et al, 2011) by
blocking the expected binding site on the RING1 domain from an E2
conjugating enzyme resulting in negligible ubiquitination activity.
Despite the apparent well-folded, compact nature of parkin in this
state, a wealth of flexibility exists within the E3 ligase that is not
obvious from the crystal structures. NMR dynamics experiments
show significant mobility for the IBR domain and segments on
either side of a short helix within the tether region where poor elec-
tron density is frequently observed in crystal data (see fig S4 in
Kumar et al, 2015). Details of the partial E3 ligase activation of
parkin have been shown in complexes with phosphorylated ubiqui-
tin (pUb; Kumar et al, 2015, 2017; Wauer et al, 2015), where pUb
binds to a broad crevasse between the RING0 and RING1 domains
(Fig 1A). The association of pUb causes rearrangement of the IBR
domain and results in the formation of a large gap between the IBR
and RING1 domains. This results in decreased mobility of the IBR
domain due to its juxtaposition with the pUb molecule as shown by
heteronuclear nOe experiments (Fig EV1) and increased mobility in
the tether region, especially residues V380-A390 that immediately
follow the IBR domain. In this optimized state, PINK1 is able to
phosphorylate the Ubl domain more efficiently (Ordureau et al,
2014; Aguirre et al, 2018) resulting in nearly 10-fold decreased affin-
ity of the pUbl domain and increased affinity for pUb at the RING0/
RING1 interface. This allosterically releases the pUbl domain from
its interaction with the RING1 domain (Kumar et al, 2015; Sauve´
et al, 2015; Aguirre et al, 2017) although no structures of this
complex for full-length parkin exist. To assess this event, the struc-
ture and dynamics of autoinhibited parkin and those of phosphory-
lated parkin in complex with pUb (pParkin:pUb) were probed by
HDX experiments measured by mass spectrometry (Fig 1B–D and
Appendix Fig S1). These experiments were used to provide a
measure of the accessibility of the backbone amides to solvent and
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the strength of hydrogen bonding in parkin. Based on previous
structural data, these experiments should probe at least three
aspects of parkin activation: (i) the binding site for the pUb mole-
cule, (ii) changes in the position of the Ubl domain upon phosphory-
lation and (iii) indirect structural changes that result from either of
these events. The HDX data, which show 91% coverage for parkin
(Appendix Fig S2), highlight that many regions of the RING0 and
RING1 domains exhibit the largest differences in their HDX proper-
ties (Fig 1C). For example, a series of peptides covering regions of
the RING0 (Y147-Q155, F209-A225) and RING1 (F277-L283, I298-
E309, Y312-E322, V324-L331) domains show slower exchange in
the pParkin:pUb state due to protection of these regions by pUb
binding at the RING0/RING1 interface (Fig 1D). Coincident with
this, peptides at the extreme C-terminus of the IBR domain (C365-
A379), the tether region (Y391-Q400) and nearly the entire Ubl
domain show increased deuterium exchange (Fig 1C and D). One
region of the Ubl domain (R42-E49) shows slower exchange upon
phosphorylation. This is likely a direct effect of phosphorylation
only since several residues in this region (I44, A46, G47) have
decreased amide exchange in the isolated Ubl domain (Aguirre et al,
2017). These observations show the pUbl domain is no longer
bound at the IBR/RING1 interface and, consistent with previous
NMR, sedimentation velocity and computational experiments, indi-
cates the pUbl domain adopts a range of bound/free conformations
in the pParkin:pUb state (Fig 1D; Caulfield et al, 2014; Aguirre et al,
2017). In this scenario, release of the pUbl domain exposes the
predicted E2~Ub binding site, based on other RING/E2 complexes
(Lechtenberg et al, 2016; Dove et al, 2017; Yuan et al, 2017).
The Parkin/UbcH7-Ub complex reveals an E2-Ub conformation
poised for Ub transfer
Phosphorylation of Ub, its recruitment to parkin and subsequent
phosphorylation of the Ubl domain result in an increased affinity
for the UbcH7~Ub conjugate (Kumar et al, 2015) used by parkin
to efficiently transfer ubiquitin to the RING2(Rcat) domain and
propagate the ubiquitination reaction. As a first step to identify
how UbcH7~Ub stimulates the transfer of its Ub cargo to the
catalytic cysteine within the RING2(Rcat) domain, we used NMR
spectroscopy to examine how the E2~Ub complex is recruited to
the R0RBR C-terminal region of parkin. This work required
multiple modes of isotopic labelling, chemical shift assignment of
the selected proteins and in some cases purification of the
assembled complexes. For example, the chemical shift assignment
of R0RBR parkin was completed using TROSY-based triple-reso-
nance experiments using 2H,13C,15N R0RBR parkin (Kumar et al,
2015). A non-hydrolysable E2~Ub conjugate was assembled using
a triple-substituted UbcH7 protein (UbcH7C17S/C86K/C137S) to allow
formation of the isopeptide linkage between the UbcH7 and Ub
(UbcH7-Ub) and prevent oxidation of the E2 enzyme during
NMR experiments. Due to the size of the complexes formed,
which compromises the quality of NMR spectra, we utilized
mixtures containing a triple-labelled (2H,13C,15N) protein titrated
with a deuterated partner. For example, 2H,13C,15N-labelled
R0RBR parkin was complexed with invisible 2H-labelled pUb and
purified to homogeneity by size-exclusion chromatography
(R0RBR:pUb) prior to the addition of 2H-labelled UbcH7-Ub
conjugate.
Initial chemical shift perturbation experiments monitored the
1H–15N TROSY spectra of the 2H,13C,15N-labelled R0RBR:2H-labelled
pUb complex with 2H-labelled UbcH7-Ub. These data show that
many resonances in R0RBR parkin shift in the presence of E2-Ub
and undergo line broadening indicative of a nearly 70-kDa complex
being formed (Fig 2A). Formation of the UbcH7-Ub complex with
R0RBR:pUb occurs with slow exchange binding kinetics indicative
of a Kd < 1 lM measured previously by isothermal titration
calorimetry (Kumar et al, 2015, 2017). Surprisingly, spectral
changes were obvious in two distinct regions of R0RBR—one region
where residues are mostly surface exposed and a second region
where residues are largely buried (Figs 2B and EV2). The first area
consists of resonances belonging to surface residues within the
RING1, IBR and tether region indicative of a canonical E2/RING E3
binding interface as well as the Ub interaction site. Resonances
affected by E2 binding were located in L1 (C241, T242), helix H1
(L266, V269-L272), L2 (C293) and the tether (Q389-R392, D394-
R396) regions of R0RBR while residues in the IBR domain (V330-
R334) and tether (A379-F381) corresponded to the Ub binding
region (Figs 2B and EV2A). The E2 binding region was verified
through separate NMR experiments that monitored the individual
binding of 2H-labelled UbcH7 with 2H,13C,15N-labelled R0RBR
(Fig EV2B). This experiment showed more limited chemical shift
changes but included distinctive line broadening and loss of signals
for the L1, helix H1 and L2 regions of the RING1 domain confirming
the E2 interaction site with little effect on resonances from residues
in the IBR domain.
Reciprocal NMR experiments were conducted to identify the
binding surfaces for the UbcH7 and Ub components within the
UbcH7-Ub conjugate upon binding to the R0RBR:pUb complex. In
these experiments, we titrated size-exclusion purified 2H-
R0RBR:2H-pUb complex into a solution of 2H,15N-labelled UbcH7-
Ub conjugate and monitored chemical shift changes using 1H–15N
TROSY NMR spectroscopy (Appendix Fig S3). These experiments
were complicated because UbcH7-Ub predominantly forms a
closed state in the absence of a binding partner, but reverts to an
open state upon binding to an RBR E3 ligase (Dove et al, 2016).
Thus, we expected to see chemical shift changes in UbcH7-Ub that
reflected both conversion to the open state and binding to R0RBR:
pUb. The closed state of UbcH7-Ub was easy to identify based on
previous experiments (Dove et al, 2016). Initial 1H–15N HSQC
spectra of the UbcH7-Ub conjugate showed numerous resonances
in UbcH7 (F22, V40, N43, N56, K100-N113) and Ub (G47-L50) that
reflect close proximity between helix H2 in UbcH7 and Ub
(Appendix Fig S4). Upon binding to R0RBR:pUb, most of these
signals return to a similar position as found in the unconjugated
(free) UbcH7 protein indicating Ub is not occupying the closed
position. These observations indicate that parkin converts the
UbcH7-Ub conjugate from the predominantly closed state to a
more open conformation, a similar observation as made for the
RBR E3 ligase HHARI (Dove et al, 2016). Indirectly this also
shows the helix H2 region (K100-N113) in UbcH7 and the K48
loop in Ub are not at the R0RBR interface. Thus these chemical
shift changes were not considered to map the binding interface in
the complex. In contrast to the changes observed for conversion of
the closed to the open states of UbcH7-Ub, titration of the R0RBR:
pUb complex into the UbcH7-Ub conjugate resulted in broadening
of many resonances. Notably, several signals in both UbcH7 and
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Ub underwent significant chemical shift changes or shifted such
that they could not be identified in spectra, where the UbcH7-Ub
conjugate was saturated with the R0RBR:pUb complex, due to
slow or slow–intermediate chemical shift exchange. These reso-
nances correspond to those in helix 1 (R6, M8 and L11), loop 4
(A59, F63) and loop 7 (N94, K96, A98) of UbcH7 and the b1-b2
loop (V5, T7, L8, T9 and I13), the linker following helix a1 (E34,
I36) and C-terminus (V70, G75) of Ub (Appendix Fig S3).
We used the results from chemical shift perturbation experiments
to determine a model of the UbcH7-Ub conjugate bound to R0RBR:
pUb using HADDOCK (Dominguez et al, 2003). This was done using
the crystal structures of R0RBR:pUb (PDB 5N2W), UbcH7 (PDB
4Q5E) and Ub (PDB 1UBQ) as starting points and imposing distance
restraints between the proteins to conduct three-molecule docking
of UbcH7 and Ub to the R0RBR:pUb complex. Distance restraints
were selected for residues that became unobservable or shifted more
A C
D
B
Figure 1. Autoinhibited and released states of pUbl prior to E2~Ub recruitment.
A Cartoon structure of optimized, inhibited parkin from X-ray crystal structure (PDB 5N2W; Kumar et al, 2017). The structure shows the Ubl (grey), RING0 (brown),
RING1 (blue), IBR (green) and RING2(Rcat; pale green) domains along with the tether region (purple). A schematic block diagram is shown above to illustrate the
domains. The pUb (yellow) molecule is shown bound to the RING0/RING1 interface. Zn atoms are shown as spheres, and regions of parkin not observed in the crystal
structure are indicated as dashed lines. The cartoon figure was created using PyMol (Delano, 2002).
B Selected examples of % deuterium uptake measured by HDX mass spectrometry to show differences between full-length autoinhibited parkin (black lines) and
phosphorylated parkin (pParkin) in complex with pUb (orange lines). Each plot shows the % deuterium uptake for the peptide indicated as a function of time.
C Differences in % deuterium uptake between autoinhibited parkin and pParkin:pUb state are plotted at the one-minute time point. The width of the bars shown
represents the length of the peptides observed and measured, while the heights represent the relative difference in hydrogen–deuterium exchange between the two
species. Error bars represent standard deviation above the average for triplicate measurements. Positive bars indicate a greater deuterium uptake in the pParkin:pUb
state compared to the autoinhibited state indicating greater exposure to solvent and/or weaker hydrogen bonding, while a negative change indicates the pParkin site
is more protected. The domain structure of parkin is shown below the data to indicate the location of peptides.
D Relative HDX differences are mapped to the structure of parkin:pUb (PDB 5N2W) where the pUbl domain has been arbitrarily positioned away from the remainder of
the protein. Regions where HDX was faster in the pParkin:pUb complex relative to parkin alone at the one-minute time point are indicated in red, while those regions
in blue exchange more slowly using the gradient shown. Several regions not visible in crystal structures were modelled into the structure using the Modeller tool
(Eswar et al, 2006) in Chimera (Pettersen et al, 2004). The arrows at the top of the figure indicate the pUbl domain samples multiple conformations based on its
overall faster HDX in the phosphorylated state and previous NMR and analytical sedimentation velocity experiments (Aguirre et al, 2017).
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than one standard deviation above the average shift (Fig EV2 and
Appendix Fig S3), and had a side chain surface exposure > 20%.
We also included neighbouring residues to those with large chemi-
cal shift changes that were solvent exposed (“passive” residues
according to the HADDOCK protocol). This resulted in a total of 23
ambiguous distance restraints between R0RBR and the UbcH7
moiety and 25 ambiguous restraints between the R0RBR and Ub
proteins. A single unambiguous restraint was used to mimic the
isopeptide bond between the carboxylate in G76 of Ub and the side
chain amine from K86 in UbcH7 during calculations. The resulting
models showed the location of the UbcH7 and Ub proteins with
respect to R0RBR:pUb is similar in all 100 water-refined complexes.
The best 20 complexes have a backbone RMSD of 0.71  0.10 for
R0RBR:pUb:UbcH7-Ub. Comparison of the structures shows that
some variation in the orientation of the Ub molecule is observed
that was not evident for R0RBR, pUb or UbcH7 proteins in the
models. This may indicate the Ub protein in the UbcH7-Ub complex
is more dynamic (Fig EV3) than the remainder of the complex. In
the lowest energy structure (Fig 2C), the UbcH7-Ub conjugate takes
on an open conformation in the complex where the UbcH7 moiety
interacts mostly with the RING1 domain and the tether region while
the Ub molecule interacts with the RING1/IBR pocket and the N-
terminus of the tether region. In the complex, helix H1 (R6, K9) and
loop L4 (E60, F63-K64) in UbcH7 contact the R0RBR loop L1 (T240,
T242) and helix H1 (L266, T270, R271, D274) respectively in RING1
(Fig 2C). As with other E2/RBR E3 ligase complexes (Lechtenberg
et al, 2016; Dove et al, 2017; Yuan et al, 2017), the L7 loop (N94,
K96, P97, A98) in UbcH7 sits adjacent to loop L2 (V290-G292) in
RING1, but has additional contacts with Y391-D394 just prior to the
short helix in the tether region. We noted that some of the largest
A
C
D
B
Figure 2.
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chemical shift changes were in this region of the tether (Y391, R392,
D394), which undergoes multiple rearrangements in crystal struc-
tures of parkin (Kumar et al, 2017). NMR dynamics experiments
(Fig EV1; Kumar et al, 2015) and a structure of the isolated IBR–
tether–RING2(Rcat) region (Spratt et al, 2013) indicate this region is
very flexible and likely adopts multiple conformations in solution.
We interpreted the chemical shift changes within the tether region
to result from both direct E2 binding and an altering of the tether
position to accommodate the E2 enzyme. The open arrangement of
the E2-Ub bound to R0RBR parkin more closely resembles the inter-
action of UbcH5b-Ub with HOIP (Lechtenberg et al, 2016) than
either of the structures for UbcH7-Ub with HHARI (Dove et al, 2017;
Yuan et al, 2017; Fig EV4). Ub binding is governed predominantly
by contacts from b1-L1-b2 (K6, L8, K11, I13-T14), the linker follow-
ing helix a1 (Q31-D32) and C-terminus (L73, R74) to an R0RBR
surface including b1 (P333, P335) and the C-terminus of the IBR
domain (E370) and adjacent tether (V380, F381, S384, T386), RING1
helix H1 (N273) and the straightened RING1 helix H3 (R314, Y318).
The Ub binding site of the IBR domain from UbcH7-Ub binding
agrees well with potential ubiquitin-binding regions (UBR2, UBR3)
inferred from crystallographic studies and supported through ubiq-
uitination activity assays (Kumar et al, 2017). Further, the location
of the Ub molecule provides insight into the next step of the ubiqui-
tination process, the transfer to the RING2(Rcat) domain. The Ub
conjugate is positioned such that two hydrophobic regions including
the I44 patch and the C-terminus (V70, L71) of Ub are pointed away
from the RING1 domain and exposed to solvent. Although not
identical, the activated Ub in the HOIP/UbcH5b complex and donor
Ub in the RING2L transfer complex are positioned similarly
(Stieglitz et al, 2013; Lechtenberg et al, 2016). These hydrophobic
regions (I44, V70, L71) are used to recruit helix hL2 from the cata-
lytic RING2L domain in the domain-swapped dimer structure
(Lechtenberg et al, 2016). This suggests that a similar mechanism
might exist for parkin whereby the RING2(Rcat) domain is reposi-
tioned adjacent to the hydrophobic sites in Ub. The orientation of
the UbcH7-Ub conjugate in our structure poises the C-terminus of
Ub for transthiolation by exposing the G76 carboxyl in the
isopeptide linkage towards the tether side of parkin. This arrange-
ment suggests that nucleophilic attack by the catalytic C431 in the
RING2(Rcat) domain would come from this direction (backside as
shown in Fig 2C). The structure also shows that helix H2 in UbcH7,
previously used to interact with Ub in the closed E2-Ub conforma-
tion, is exposed on the same side as the C86K-G76 linkage. Overall,
the current structure shows how UbcH7 might position its Ub cargo
for transfer to the catalytic cysteine (C431) of the RING2(Rcat)
domain and provides clues that suggest the RING2(Rcat) domain is
eventually repositioned near the UbcH7-Ub conjugate to promote
Ub transfer.
In order to further test the parkin recruitment site for UbcH7-Ub
observed in our models, a series of ubiquitination assays were
performed. We first analysed the observed ubiquitin surface
involved at the Parkin:UbcH7-Ub interface using distinct assays that
monitor transfer of ubiquitin from the E2 onto parkin and subse-
quently onto the substrate. To assess UbcH7 mediated ubiquitin
loading of parkin, we generated a pParkin RING2(Rcat) mutant
(C431S + H433A, referred to as pParkinCH) that is able to trap an
E3~Ub oxyester intermediate (Spratt et al, 2013; Kumar et al, 2017).
We rationalized that ubiquitin loading to pParkinCH would depend
on the interaction of Ub in the UbcH7~Ub conjugate with pParkin.
In the presence of ATP, E1, UbcH7 and wild-type ubiquitin, we
observe the formation of a pParkinCH~Ub species in both the
absence and presence of pUb (Fig 2D, top). In contrast, alanine
mutants of ubiquitin b1-L1-b2 residues (K6A, L8A, K11A) observed
at the Ub interface with the parkin IBR domain result in defective
ubiquitin transfer onto parkin even in the presence of pUb. Conse-
quently, these ubiquitin mutants were also compromised in
pParkin-mediated substrate (HA-tagged Miro1181–579) ubiquitination
(Fig 2D, bottom). The ubiquitin mutant E34A shows minimal effects
suggesting the C-terminus of the long helix in Ub has a lesser role in
directing the Parkin:UbcH7~Ub interface. A similar observation was
made for the HOIP:UbcH5b-Ub complex (Lechtenberg et al, 2016).
In a complementary approach, we tested the UbcH7-Ub interface
with parkin by using ARJP and non-ARJP parkin variants to assess
E3 ligase activity (Fig 2E). All assays were done in the absence and
◀ Figure 2. Model of the E2-Ub conjugate bound to pUb-activated parkin.A Portion of the 1H–15N TROSY NMR spectrum showing signals from R0RBR parkin within the R0RBR:pUb complex (black) and in the presence of one equivalent of the
unlabelled UbcH7-Ub conjugate (blue). Signals that shift in the presence of UbcH7-Ub are indicated by arrows. Some signals shift and broaden and cannot be
identified in the bound state. Boxes indicate signals that have shifted and are visible at very low contour level.
B Two distinct surfaces are revealed on parkin upon binding of the UbcH7-Ub conjugate. Chemical shift perturbations were measured from 1H–15N TROSY spectra of
2H,13C,15N-labelled R0RBR parkin bound to unlabelled pUb in the absence and presence of one equivalent unlabelled UbcH7-Ub. Chemical shift perturbations
(absence of signal, average shift + 1 SD) are modelled onto the surface of R0RBR bound to pUb (PDB 5N2W). The UbcH7-Ub binding site comprises the RING1 and
IBR regions (magenta). An adjacent site composed of many buried residues was also observed (cyan) that results from E2-Ub binding but does not include the E2
binding site. Sections of the tether and linker regions not visible in the crystal structure were added using Modeller (Eswar et al, 2006) so that chemical shift changes
for residues not observed in crystal structures could be mapped.
C Model of R0RBR:pUb in complex with UbcH7-Ub derived from NMR chemical shift data and HADDOCK docking (Dominguez et al, 2003). The lowest energy structure
is shown, and the top 20 structures all showed excellent agreement (RMSD 0.71  0.1 Å) although some minor differences were noted for the orientation of the Ub
molecule. The structure shows that UbcH7-Ub binds in an open conformation. UbcH7 uses canonical E2-RING E3 interactions that include residues from two loops in
the RING1 domain (L1, L2) and two loops in the E2 enzyme (L4, L7) to stabilize the interaction. Ub binds to a RING1/IBR pocket. In this model, no attempt was made
to move or re-orient any of the domains in parkin.
D Effects of ubiquitin surface mutants based on the UbcH7-Ub:R0RBR:pUb model for the ubiquitin loading and off-loading potential of pParkinCH (pParkinC431S,H433A).
Coomassie-stained gels (top) depict the formation of a pParkinCH~Ub oxyester intermediate after 60 min in the absence and presence of pUb using the indicated
ubiquitin species. Anti-HA blots (bottom) depict the ubiquitination of HA-tagged Miro1181–579 by pParkin after 10 min in the absence and presence of pUb using the
indicated ubiquitin species. The E24A substitution in Ub is a negative control as this residue faces away from the interface with parkin.
E Autoubiquitination assay for parkin using ARJP and non-ARJP substitutions in parkin observed near the interface with UbcH7-Ub. Assays were done in the absence
and presence of pUb. Experiments with PINK1 were done by treating parkin:pUb with PINK1 for 30 min prior to adding other reagents needed for ubiquitination.
Assays were monitored using a DyLight-labelled Ub protein and measuring fluorescence at 800 nm.
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presence of pUb or with PINK1 preincubated with parkin and pUb
to enable phosphorylation of the Ubl domain. As expected, signifi-
cant increases in ubiquitination were observed in the presence of
both phosphorylation steps. ARJP variant T240R in the RING1 helix
H1 shows significant decreases in activity due to disruption of inter-
actions with F63 and P97 in UbcH7. The P335G/C337G substitution
in parkin expected to disrupt one of the Zn-binding sites in the IBR
domain that interacts with K11, T13 and I14 of ubiquitin also had
diminished activity. The R271S substitution that is near the UbcH7
L4 loop in our structure had a minor decrease consistent with modi-
fication of that interaction. The activity of two other substitutions,
N273S and R314A, had similar activities to that of the wild-type E3
ligase, likely a reflection of a weakened interaction with the Ubl
facilitating its phosphorylation and stimulating ubiquitination as
previously observed (Sauve´ et al, 2015).
UbcH7-Ub binding leads to a re-modelled RING0/RING2 interface
in parkin
In addition to the UbcH7-Ub binding site on parkin, analysis of
chemical shift perturbation experiments of 2H,13C,15N-labelled
R0RBR:pUb upon addition of UbcH7-Ub reveals many changes
localized at the interface between the C-terminus of the tether
region (A398-T414), RING0 (S145, F146), RING1 (Q252, R256,
H257) and RING2(Rcat; T415, E426, K427, N428, D464; Figs 2B,
and 3A and B). In contrast, NMR experiments performed between
2H,13C,15N-labelled R0RBR:pUb and unconjugated UbcH7 revealed
many of these chemical shift perturbations are absent, or present
to a lesser extent (Fig EV2), suggesting the intact UbcH7-Ub conju-
gate is necessary to induce these additional changes. Three-dimen-
sional structures show that most of the affected residues form a
cluster anchored by W403 that follows the short helix in the tether
region and is essential for packing the tether against the RING0/
RING1/RING2(Rcat) core (Fig 3A and B). In the absence of Ub or
Ubl phosphorylation by PINK1, a W403A parkin variant dramati-
cally increases ubiquitination activity (Trempe et al, 2013), likely
a result of a structural rearrangement near W403 and exposure of
the subsequent catalytic C431 in the RING2(Rcat) domain. There-
fore, we hypothesized that UbcH7-Ub binding to R0RBR:pUb might
cause a similar rearrangement near the RING0/RING1/RING2
(Rcat) core in the wild-type protein as in the W403A substituted
version (R0RBRW403A). To test this, we compared the positions of
resonances from a 15N-labelled R0RBRW403A HSQC spectrum with
those from a 15N-labelled R0RBR spectrum (Appendix Fig S5).
Remarkably, in the R0RBRW403A data many signals from residues
that neighbour W403 are either undetectable or undergo signifi-
cant chemical shift changes similar to those observed upon
UbcH7-Ub binding to R0RBR:pUb but not directly at the E2 bind-
ing site. The similarity of the chemical shift changes and the
buried nature of many of these residues suggest the RING0/
RING1/RING2(Rcat) interface is re-modelled during the E2~Ub
interaction with parkin.
The UbcH7-Ub conjugate enhances pUbl domain re-binding
to parkin
Upon presentation of pUb and phosphorylation of the Ubl domain
of parkin, both HDX and NMR dynamics experiments show the
pUbl domain is dislodged from the autoinhibitory site against the
IBR and RING1 domains. This is supported by the nearly 10-fold
poorer affinity of the Ubl domain for R0RBR parkin upon phospho-
rylation (Kumar et al, 2015). In order to test how the UbcH7-Ub
conjugate might alter the interaction of the pUbl domain with the
remainder of the E3 ligase, we again used HDX mass spectrometry
experiments of phosphorylated parkin bound to pUb (pParkin:
pUb), this time in the presence of UbcH7-Ub. The dissociation
constant for this complex is near 0.5 lM, so these experiments
were done using 10 lM pParkin:pUb in the presence of non-hydro-
lysable UbcH7-Ub (10 lM) to achieve more than 80% saturation
of pParkin:pUb with the E2-Ub conjugate during HDX measure-
ments.
In the presence of the E2-Ub complex, the majority of parkin
shows greater exchange than the phosphorylated, activated state
(Fig 4A and Appendix Fig S6). In general, this indicates that a global
rearrangement has occurred in the protein, stimulated by UbcH7-Ub
conjugate binding. For example, the HDX data show significant
increases in exchange for the RING0 and RING2(Rcat) domains.
This observation is incongruous with current structures of parkin,
and our HDX data for pParkin:pUb, that show most of these
domains are protected from solvent and not exposed. In contrast,
these regions correspond closely to the RING0/RING1/RING2(Rcat)
interface with the tether region suggested to be re-modelled based
on NMR chemical shift perturbation experiments (Fig 3A and B).
The increase in deuteration upon UbcH7-Ub binding indicates this
interface is becoming much looser with a loss of both hydrophobic
and hydrogen bonding interactions. One possible interpretation of
this result is that the RING2(Rcat) domain is displaced from the
interface exposing its surface, the RING0 interface with RING2(Rcat)
and the C-terminus of the tether (Fig 4B).
Coincident with the changes in HDX for the RING0 and RING2
(Rcat) domains, numerous increases are noted near the pUb inter-
face with the RING0/RING1 cleft and extending towards the IBR
domain. These regions undergo multiple rearrangements in struc-
ture and orientation upon pUb and Ubl binding (Kumar et al, 2015;
Wauer et al, 2015; Kumar et al, 2017). The increase in HDX could
indicate further rearrangement occurs upon UbcH7-Ub binding lead-
ing to a more extended structure. The HDX experiments also show
that the pUbl domain remains exposed to solvent. One exception is
the C-terminus of the pUbl domain (D62-M80) that is significantly
more protected. This region contains the phosphorylated S65
residue suggested to interact with three basic residues (K161, R163
and K211) in the RING0 domain that show attenuated parkin
autoubiquitination when substituted (Wauer et al, 2015). Two of
these sites are locations of ARJP substitutions (K161N, K211R,
K211N). A minority of parkin crystal structures also show a bound
sulphate ion in this area. Although we did not observe a decrease in
HDX in this region of the RING0 domain, the decreased exchange in
the N-terminus of the pUbl domain could be consistent with
increased binding to the RING0 domain stimulated by the UbcH7-Ub
conjugate.
To test how UbcH7-Ub binding might influence the potential
relocation of the pUbl domain, we examined a series of 1H–15N
HSQC spectra for 15N-labelled phosphorylated parkin in complex
with unlabelled pUb and compared this to the isolated pUbl
domain. We then compared spectra of 15N-labelled pUbl in the
absence and presence of R0RBR:pUb and UbcH7-Ub. In full-length
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phosphorylated parkin, the 1H–15N HSQC spectrum is very
complicated due to a large number of signals that are visible
from the highly flexible linker and tether regions in the protein
(Fig 4C). However, nearly all signals are visible from the pUbl
domain in the full-length protein when a short relaxation delay is
used in the HSQC experiment to suppress broad signals arising
from the compact, folded R0RBR region (see also fig S9 in
Aguirre et al, 2017). When compared to the 1H–15N HSQC spec-
trum of the isolated pUbl domain (Fig 4C), it is clear that very
small chemical shift changes and decreases in intensities occur
for residues pSer65, D62, Q63 and Q64, consistent with a weak
interaction of the pUbl with the remainder of the protein.
However, many other signals from the pUbl are hardly attenuated
(Aguirre et al, 2017). These observations are consistent with our
HDX experiments, which indicate the pUbl domain spends most
of its time dissociated from the remainder of the protein in the
absence of an E2-Ub conjugate (Fig 1D).
When the 1H–15N HSQC spectrum of 15N pUbl is compared to
that with added R0RBR:pUb, we observe no significant chemical
shift changes (Fig 4D). This supports previous observations of a
weak interaction for the pUbl domain with R0RBR parkin in trans
(Kumar et al, 2015; Sauve´ et al, 2015). Upon addition of UbcH7-Ub,
we observe small but measurable changes for the positions of
several signals including pSer65, D62, Q63 and Q64 (Fig 4D). These
chemical shift changes occur on the fast exchange timescale consis-
tent with weak binding of the pUbl domain to R0RBR parkin that is
accentuated upon UbcH7-Ub recruitment by the E3 ligase. This indi-
cates that the pUbl domain undergoes a weak interaction with the
remainder of the parkin protein that is stimulated through binding
of the UbcH7-Ub conjugate.
UbcH7-Ub and pUbl work together to modulate C431 reactivity
Our NMR experiments using R0RBR parkin allowed us to determine
the UbcH7~Ub binding site within parkin as one requirement for
ubiquitination and have identified how UbcH7-Ub binding might
re-model the RING0/RING1/RING2(Rcat) interface with the tether.
However, in the absence of the pUbl domain these experiments are
deficient in establishing how the pUbl might work with an E2~Ub
conjugate to achieve optimal activity. In particular, all three-dimen-
sional structures to date have been unable to show how the reactiv-
ity of the catalytic C431 residue in the RING2(Rcat) domain might
be altered upon phosphorylation of the Ubl domain and addition of
the E2~Ub conjugate. In order to assess this, we examined the abil-
ity of full-length parkin and R0RBR parkin to form a non-hydroly-
sable ubiquitin adduct using ubiquitin~vinyl sulphone (UbVS).
Although smaller probes to test E3 ligase activity are available (Pao
et al, 2016), we used UbVS to mimic the parkin-Ub product that
would be expected following Ub transfer from the UbcH7 enzyme.
Using different combinations of parkin, phosphorylated parkin,
phospho-ubiquitin and UbcH7-Ub, this approach tested the reactiv-
ity, and hence accessibility, of the catalytic C431 in the RING2
(Rcat) domain during each step of the parkin activation cycle
(Fig 5).
As expected, autoinhibited and pUb-bound parkin or R0RBR
showed minimal reaction with UbVS (Fig 5 and Appendix Fig S7) in
agreement with previous three-dimensional structures and reactivity
profiles that indicate the catalytic C431 is mostly occluded by neigh-
bouring RING0 domain interactions (Riley et al, 2013; Wauer &
Komander, 2013). Remarkably, phosphorylated parkin activated by
pUb shows rapid product formation with UbVS (Fig 5A and B),
A B
Figure 3. UbcH7-Ub binding induces re-modelling of the RING0/RING2(Rcat) interface.
A Selected regions from 1H–15N TROSY spectra of 2H,13C,15N-labelled R0RBR parkin bound to unlabelled pUb in the absence (black contours) and presence (blue
contours) of one equivalent invisible 2H-labelled UbcH7-Ub. A large number of signals for residues including S145, N235, S255, E399, Q400, W403, E404 and D464
either shift or are absent in spectra with UbcH7-Ub.
B Details of the re-modelled region in parkin observed upon UbcH7-Ub binding. The figure shows the side chains of residues in the RING0 (brown), RING1 (blue), tether
(purple and RING2(Rcat; pale green) interface that surround W403 (red) and are most affected by UbcH7-Ub binding.
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visible even after 1 min (not shown). A similar reaction with
R0RBR:pUb when the parkin pUbl domain is added in trans shows
little modification with UbVS even after 60 min (Fig 5C and D). The
most logical explanation for these observations is that the pUbl
domain is facilitating access of the UbVS probe to the catalytic C431
site in the RING2(Rcat) domain by binding to another region in
parkin. Since the pUbl interaction exhibits a weaker affinity in trans,
the effect of the UbVS probe is much lower than observed for the
intact protein. Interestingly, introduction of UbcH7-Ub to either the
pParkin:pUb sample (Fig 5A and B) or the pUbl:R0RBR:pUb
complex (Fig 5C and D) leads to opposite results. In the full-length
protein, we observe a reproducible lower conversion rate in the
presence of the E2-Ub conjugate than in its absence (Fig 5A and B).
In the pUbl:R0RBR:pUb sample, the reactivity to UbVS is enhanced
in the presence of UbcH7-Ub (Fig 5C and D). At a minimum, this
shows that the pUbl domain and E2-Ub act synergistically to alter
the reactivity of the catalytic C431 residue in the RING2(Rcat)
domain. Introducing the “activating” W403A mutation did not
A B
C D
Figure 4. Interaction of the pUbl domain is facilitated by UbcH7-Ub recruitment.
A Differences in % deuterium uptake between the pParkin:pUb and pParkin:pUb in complex with UbcH7-Ub states plotted at the one-minute time point. The
width of the bars shown represents the length of the peptides observed and measured, while the heights represent the relative difference in
hydrogen–deuterium exchange between the two species. Error bars represent standard deviation above the average for triplicate measurements. Positive
bars indicate a greater deuterium uptake in the pParkin:pUb:UbcH7-Ub state compared to the pParkin:pUb state, signifying a greater exposure to solvent,
while a negative change indicates the complex state is more protected. The linear domain structure is shown below the data to indicate the location of
peptides.
B Relative HDX differences from (A) are mapped to the structure of pParkin:pUb and UbcH7-Ub complex. Regions where HDX is faster in the pParkin:pUb:UbcH7-Ub
complex at the one-minute time point are indicated in red, while those regions in blue exchange more slowly using a similar the gradient as Fig 1. Based on HDX
and NMR experiments (C, D), the pUbl domain is shown oriented towards the RING0 domain (dashed arrow, top). The increased HDX for RING2(Rcat) and RING0
suggests the RING2(Rcat) domain has a weaker interaction with the RING0/RING1 domains upon UbcH7~Ub binding (dashed arrow, bottom). Regions shown in grey
are peptides that were not mapped.
C 1H–15N HSQC spectra of full-length 15N-labelled pParkin:pUb (green contours) compared to that for the isolated 15N-labelled pUbl domain (grey contours). The
spectrum of the full-length pParkin:pUb complex was collected using a 1H–15N CPMG, T2-filtered HSQC (Aguirre et al, 2017) to show only the more mobile regions of
pParkin. In the spectrum of full-length pParkin, many additional resonances arising from flexible loops in the protein are observed and are not labelled for clarity.
Residues that experience small chemical shift changes are indicated by arrows.
D 1H–15N HSQC spectra of 15N-labelled pUbl (grey contours) and in the presence of an equimolar amount of unlabelled R0RBR:pUb (blue contours) show little
change. Upon addition of unlabelled UbcH7-Ub (red contours), small changes in chemical shifts of pSer65, D62, Q63 and Q64 are observed as indicated by
arrows.
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significantly increase reactivity with the UbVS probe, suggesting the
re-modelling observed in our NMR experiments may not directly
expose parkin’s catalytic Cys431 (Appendix Fig S7). In agreement
with our NMR data (Fig 4), the E2-Ub conjugate has the ability to
re-model the RING0/RING2(Rcat) interface and increase binding of
the pUbl domain in trans that results in increased reactivity of the
catalytic C431 residue. Meanwhile, the small decrease in C431
accessibility in the pParkin:pUb complex in the presence UbcH7-Ub
suggests a further conformational change occurs due to E2~Ub bind-
ing that decreases the availability of the catalytic site. This is in
agreement with our HDX experiments that suggest a reorganization
of the RING2(Rcat) domain (Fig 4).
Discussion
Although parkin was originally thought to be a constitutively active
enzyme, it is now known to regulate its activity through intramolec-
ular domain–domain interactions and binding to effectors (Chaugule
et al, 2011; Kumar et al, 2015; Sauve´ et al, 2015). In particular,
PINK1 regulates parkin activity through phosphorylation of the Ubl
domain, and of ubiquitin itself (Kumar et al, 2015; Sauve´ et al,
2015; Wauer et al, 2015; Kumar et al, 2017), which then acts as an
effector. Multiple structures of autoinhibited parkin reveal that the
E2 binding site is blocked; however, static crystal structures have
shown that binding to pUb does not render the proposed E2 binding
site, nor the phosphorylation site in the Ubl domain accessible
(Fig 6A). Comparison of crystal structures in the absence/presence
of the Ubl domain reveals reorganization of residues between the
RING0/RING1 interface and multiple arrangements of the IBR
domain, shown to be flexible by previous NMR dynamics experi-
ments (Kumar et al, 2015). Though pUb binding to parkin decreases
the affinity of R0RBR for the Ubl domain, it is not sufficient to
dislodge the Ubl domain in the crystal (Kumar et al, 2015, 2017).
Rather, this step optimizes parkin for Ubl phosphorylation and
E2~Ub engagement (Fig 6B; Kumar et al, 2015; Ordureau et al,
2015). It is well established that phosphorylation of the Ubl domain
following pUb recruitment significantly increases its ubiquitination
activity (Kondapalli et al, 2012; Shiba-Fukushima et al, 2012; Kane
et al, 2014; Kazlauskaite et al, 2014; Koyano et al, 2014). Current
NMR dynamics analysis of R0RBR parkin:pUb as a proxy for this
state shows the IBR domain is considerably less mobile due to
engagement with pUb although a large stretch of the tether region
remains mobile, an observation not obvious from current crystal
structures. In full-length phosphorylated parkin bound to pUb
(“Partial Activation”; Fig 6C), current and other HDX experiments
A B
C D
Figure 5. The pUbl domain and UbcH7-Ub synergistically modulate catalytic C431 reactivity.
A Exposure of the catalytic Cys431 is parkin as assessed by reaction with a UbVS probe. The different stages of activation using parkin, parkin:pUb, pParkin:pUb and
pParkin:pUb in combination with an isopeptide-linked UbcH7-Ub conjugate are indicated above each gel. Following addition of UbVS, samples were taken at the
times indicated (0–10 min) and visualized by SDS–PAGE.
B Relative percentages of pParkin and the pParkin-Ub adduct as a function of time. Intensity percentages were calculated as a function of total intensity of pParkin-Ub,
parkin and UbVS/pUb bands. Error bars represent standard deviation from the average for duplicate measurements.
C Exposure of the catalytic Cys431 is R0RBR parkin as assessed by reaction with a UbVS probe. The different stages of activation using R0RBR, R0RBR:pUb, R0RBR:pUb:
pUbl and R0RBR:pUb:pUbl in combination with an isopeptide-linked UbcH7-Ub conjugate are indicated above each gel. Following addition of UbVS, samples were
taken at the times indicated (0–60 min) and visualized by SDS–PAGE.
D Relative percentages of R0RBR and the R0RBR-Ub adduct as a function of time. Intensity percentages were calculated as a function of total intensity of the R0RBR-
Ub, R0RBR and UbVS/pUb/pUbl bands.
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(Gladkova et al, 2018; Sauve´ et al, 2018) show that the pUbl
domain is nearly completely exposed to solvent in this state
compared to its position in autoinhibited parkin where it is
surrounded by the RING1, IBR and tether regions. This interpreta-
tion agrees with NMR relaxation data, analytical centrifugation
experiments and computational work that conclude the pUbl
domain samples a large conformational space that includes weak
interaction with other regions of parkin (Caulfield et al, 2014;
Aguirre et al, 2017; Fig 6C). While this manuscript was under
review, two crystal structures of partially activated parkin appeared,
which showed the pUbl domain has the ability to bind to the RING0
domain (Gladkova et al, 2018; Sauve´ et al, 2018) comprised of a
previously identified (Wauer & Komander, 2013) basic patch (K161,
R163, K211) that included two ARJP substitutions. Mutation of these
residues renders parkin unreactive with an E2-based activity probe,
consistent with a requirement for pUbl interaction (Pao et al, 2016).
Yet other experiments show parkin retains appreciable ubiquitina-
tion ability in the absence of its Ubl domain (Chaugule et al, 2011;
Kazlauskaite et al, 2014; Kumar et al, 2015), suggesting phosphory-
lation and the Ubl domain itself are less important. Our NMR data
of full-length pParkin:pUb (Fig 5) indicate the native interaction of
the pUbl domain with the RING0 domain is weak in this state in
agreement with previous affinity experiments (Kumar et al, 2015;
Sauve´ et al, 2015). Consistent with this, it was necessary to remove
the entire RING2(Rcat) domain and the tether region from parkin in
recent structures in order to capture the bound pUbl state (Gladkova
et al, 2018; Sauve´ et al, 2018), suggesting removal of the RING2
(Rcat) domain may enhance the pUbl interaction through removal
of steric hinderance.
One of the main outcomes of pUb recruitment and subsequent
phosphorylation of the Ubl domain is to unmask the RING1 binding
site for the E2 conjugating enzyme and rearrangement of the IBR
domain to engage the conjugated Ub molecule (Kumar et al, 2015;
Kumar et al, 2017). This interaction with UbcH7-Ub shows that the
donor Ub is in the open conformation favoured by RBRs (Dove et al,
2016). The interaction site of UbcH7 with the RING1 domain in our
structure is in agreement with previous crystal structures of HOIP
with UbcH5b-Ub (Lechtenberg et al, 2016) and HHARI with UbcH7-
Ub (Dove et al, 2017; Yuan et al, 2017) although minor orientation
differences occur. This likely arises due to differences in the L2 loop
regions of the RBR E3 ligases as previously noted (Spratt et al, 2014;
Dove et al, 2016), and in particular differences in the linchpin
residue that directs the E2~Ub conjugate to its open state during
interaction (Dove et al, 2017). The position of the UbcH7 enzyme
(in UbcH7-Ub) with parkin is also nearly identical to a recent struc-
ture of truncated parkin in complex with an unconjugated E2
enzyme (Sauve´ et al, 2018). This indicates the donor Ub does not
play a major role in directing the E2 binding in agreement with its
poor binding affinity for parkin on its own.
Our NMR data indicate that UbcH7-Ub binding to partially acti-
vated parkin re-models the hydrophobic cluster involving W403 in
the tether region at the junction of the RING0/RING1/RING2(Rcat)
domains. This is supported by substitution of W403 that produces
NMR chemical shift changes analogous to those for binding of
UbcH7-Ub. Further, experiments using an E2-based activity probe
show a W403A substitution can partially recapitulate catalytic
cysteine labelling of parkin even in the absence of Ubl domain phos-
phorylation (Pao et al, 2016).
Together these observations suggest that it is the E2~Ub binding
step that induces a conformational change in the W403 cluster
(Fig 6D), rather than W403 being re-modelled to allow E2~Ub
engagement, that facilitates the interaction of the pUbl domain with
the RING0 domain of parkin. Although this step could not be shown
in recent crystal structures that lacked the RING2(Rcat) domain and
tether regions, our HDX data show that both phosphorylation and
E2-Ub binding together lead to nearly complete exposure of the
RING2(Rcat) domain. The interplay between pUbl and E2~Ub bind-
ing to modulate ubiquitination efficiency is also borne out from the
reactivity of the catalytic cysteine (C431) in RING2(Rcat) to react
with a ubiquitin probe. In R0RBR parkin, reactivity required both
A B C D E
Figure 6. Model of parkin activation by combined pUbl and E2~Ub interactions.
A Autoinhibited state whereby the Ubl domain masks the E2 binding site on the RING1 (R1) domain as described by Chaugule et al (2011) and supported through
crystallographic studies.
B Optimization step controlled by PINK1 phosphorylation of ubiquitin (Ub) and subsequent binding of pUb to the RING1/IBR interface resulting reorganization of the
RING0/RING1 interface and movement of the IBR domain. Steps (A) and (B) have been previously described.
C PINK1 phosphorylation of the Ubl domain causes its dissociation from the RING1 binding site allowing it to sample a large conformational space in solution
including weak binding to the RING0 domain favouring an uncovering of the catalytic cysteine C431.
D E2~Ub binding to the RING1/IBR domains making use of a cryptic ubiquitin binding site uncovered through dissociation of the pUbl domain. Re-modelling of the
RING0/RING1/RING2(Rcat) interface with the tether region occurs based on NMR chemical shift data and HDX experiments.
E Fully activated state of parkin utilizes synergistic binding of pUbl domain to the RING0 domain observed in crystal structures (Gladkova et al, 2018; Sauvé et al, 2018)
and E2~Ub binding that re-models the RING0/RING1/RING2(Rcat) interface to maximize accessibility to the catalytic cysteine.
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pUbl and E2-Ub addition for adduct formation. In similar NMR
experiments, addition of E2-Ub was required to observe binding of
pUbl to R0RBR parkin. The fast exchange observed in current NMR
experiments between the pUbl domain and the RING0 site observed
in crystal structures (Gladkova et al, 2018; Sauve´ et al, 2018)
suggests that this interaction is short-lived. We suggest that upon
E2~Ub recruitment, the RING2(Rcat) domain is dislodged to provide
a more optimal binding site for the pUbl domain. Indeed, one recent
structure shows that an additional segment of the linker that
precedes the RING0 domain takes the place of the RING2(Rcat)
domain (Gladkova et al, 2018), perhaps providing an extra level of
regulation. Taken together, we suggest that pUbl binding alone to
the RING0 domain is not sufficient to drive the conformational
changes required and that E2~Ub binding is necessary to re-model
the W403 region for full activation (Fig 6D and E). These events
show that both E2~Ub binding and pUbl recruitment to the RING0
domain act synergistically to propagate the ubiquitination reaction.
Recruitment of the UbcH7-Ub conjugate to pParkin:pUb appears
to cause a significant conformational change based on HDX and
NMR chemical shift experiments. An unresolved question then is:
What is the conformational change that occurs that allows ubiquitin
transfer from the E2 conjugating enzyme to the RING2(Rcat)
domain? It is tempting to consider that the RING2(Rcat) domain
repositions itself nearby the open E2~Ub conjugate to accept the
donor ubiquitin. In the absence of data to directly show this, several
lines of evidence suggest this is a possibility. For example, our HDX
data show that although the RING2(Rcat) domain is exposed in the
presence of UbcH7-Ub, its extreme C-terminus (E452-W462) is more
protected compared to that in the absence of E2-Ub. This portion of
parkin has been suggested to form important interactions with the
E2~Ub conjugate based on the similarity of hydrophobic residues
with HOIP and the position of the swapped RING2L domain in HOIP
that neighbours the UbcH5b-Ub conjugate (Lechtenberg et al, 2016).
UbVS experiments show that the reactivity of C431 in RING2(Rcat)
is slightly diminished in the presence of UbcH7-Ub (compared to its
absence in pParkin:pUb), suggesting possible rearrangement and
protection might impede its reactivity in this assay. Further, the
region immediately preceding the RING2(Rcat) domain contains a
ubiquitin-binding motif (Chaugule et al, 2011) that harbours at least
one ARJP substitution (T415N) that impairs all ubiquitination activ-
ity (Matsuda et al, 2010). A similar ubiquitin-binding motif has been
observed for HHARI, and substitutions in this region show signifi-
cant decreases in Ub affinity and ubiquitination activity (Dove et al,
2016). Although unstructured in parkin, the corresponding region in
HOIP forms a short a-helix (helix hL2) that interacts with the I44
patch of the donor Ub in the UbcH5b-Ub complex. These observa-
tions hint at a catalytic complex where interactions between both
components of the UbcH7~Ub conjugate are important for recruit-
ment of the tether and RING2(Rcat) regions. Alternatively, multiple
studies have suggested that the ubiquitin-transfer complex is more
complicated and requires co-operation between multiple parkin and
E2~Ub molecules (Lazarou et al, 2013; Kumar et al, 2017) to facili-
tate ubiquitin transfer. An attractive feature of this model, which
also utilizes alternate ubiquitin binding sites, is that it provides a
framework for the processivity of autoubiquitination observed for
parkin. With this in mind, it is worth noting that recent crystal struc-
tures lack structural resolution of several linkers in parkin that
preclude identification of intra- vs. intermolecular interactions of
the pUbl or E2 enzyme with the RING0 or RING1 domains, respec-
tively (Gladkova et al, 2018; Sauve´ et al, 2018). By the same note,
our NMR-based model of UbcH7-Ub in complex with R0RBR:pUb is
unable to identify how the tether and RING2(Rcat) might be rear-
ranged upon UbcH7-Ub and pUbl engagement. Nevertheless, our
study shows that synergy exists between these two effectors to fully
control parkin activity. Understanding the next steps in detail will
be essential to target this important enzyme for modulation during
the pathogenesis of Parkinson’s disease.
Materials and Methods
Protein constructs and purification
Full-length human parkin (1–465), Ubl (1–76), R0RBR (141–465),
Drosophila melanogaster RING2 (410–482) and other parkin variants
were expressed and purified as described previously (Chaugule et al,
2011; Spratt et al, 2013). Briefly, His-smt3-parkin constructs were
expressed in BL21(DE3) cells at 37°C to an OD600 of 0.8. Expression
was induced at 16°C with 25 lM IPTG for parkin, 0.1 mM IPTG for
R0RBR and 0.5 mM IPTG for Ubl or RING2 for 18 h. All growths,
except the Ubl domain, were supplemented with 0.5 mM ZnCl2.
Purification utilized an initial HisTrap FF column followed by Ulp1
cleavage at 4°C, a second HisTrap FF column and final Superdex 75
10/300 size-exclusion chromatography. Selectively 2H,13C,15N-
labelled R0RBR:pUb or R0RBR and selectively 2H,13C,15N or 2H,15N-
labelled Ub, UbcH7 or UbcH7-Ub were expressed and purified as
previously described (Kumar et al, 2015).
His-tagged Uba1 was expressed in BL21(DE3)CodonPlus-RIL cells
at 37°C to an OD600 of 0.8. Expression was induced with 0.5 mM
IPTG at 18°C for 12 h. His-tagged Uba1 was purified on a HisTrap
FF column by washing with a buffer containing 50 mM Tris,
200 mM NaCl, 250 lM TCEP and 25 mM imidazole (pH 8.0) and
then washing with 14% of elution buffer that contained 250 mM
imidazole. The His-tagged Uba1 was then eluted with 100% elution
buffer and stored in aliquots at 80°C for ubiquitination assays.
His-TEV-tagged human UbcH7C17S,C86K,C137S was expressed in
BL21(DE3)CodonPlus-RIL cells at 37°C to an OD600 of 0.8, and
expression was induced with 1 mM IPTG at 30°C for 18 h. UbcH7
was purified on a HisTrap FF column, cleaved at 4°C overnight and
purified on a second HisTrap FF column. His-tagged Ub was
expressed in BL21(DE3)CodonPlus-RIL cells. Complexes that
contained 1:1 R0RBR:pUb were formed using a 1.5-fold excess pUb
compared to R0RBR in a buffer containing 20 mM Tris, 75 mM NaCl
and 250 lM TCEP (pH 8). The 1:1 complex mixture was purified on
a Superdex 75 10/300 size-exclusion column to ensure excess pUb
was not present in samples for NMR studies.
Glutathione S-transferase (GST)-HA-tagged human Miro1 (resi-
dues 181–592) was expressed in BL21(DE3) cells purified using
standard protocols (Kumar et al, 2015). The GST tag was removed
using GST-3C protease, and the cleaved material was further puri-
fied on a Superdex 200 Increase 10/300 size-exclusion column.
Protein phosphorylation
Phosphorylation of Ub, Ubl and parkin was done using purified
Pediculus humanus PINK1 (126–575) as described previously
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(Kumar et al, 2015; Aguirre et al, 2017). For pUb and pUbl (1–76),
typically 10 lM PINK1 was sufficient to stoichiometrically phospho-
rylate either 100 lM Ub or Ubl in 1 h at 24°C. For parkin, typically
75 lM PINK1 was sufficient to phosphorylate 150 lM parkin for
3.5 h at room temperature. Reactions were visualized by Phos-tag
gel. PINK1 was removed using a GSTrap FF column. Phosphorylated
proteins were purified using a Superdex 75 10/300 size-exclusion
column and confirmed by mass spectrometry.
Synthesis of UbcH7-Ub isopeptide-linked conjugate
UbcH7-Ub isopeptide-linked conjugate was synthesized using an
optimized version of the protocol of Plechanovova´ et al (2012).
Briefly, 200 lM His-tagged Ub, 400 lM UbcH7C17S/C86K/C137S, 25 lM
non-cleavable His-tagged Uba1 and 10 mM Mg2+/ATP were incu-
bated together in a buffer containing 50 mM CHES and 150 mM
NaCl (pH 9.0) at 37°C for 6–16 h to form approximately 60%
UbcH7-Ub isopeptide-linked conjugate based on SDS–PAGE analy-
sis. The resulting mixture was passed through a HisTrap FF column
to eliminate unconjugated UbcH7. The eluted His-tagged proteins
were TEV-cleaved overnight at 4°C. The mixture was purified on a
second HisTrap FF column to eliminate non-cleavable His-tagged
Uba1. The remaining UbcH7-Ub was separated from unreacted Ub
using a HiLoad Superdex 16/60 size-exclusion column.
NMR experiments
All NMR data were collected at 25°C on a Varian Inova 600-MHz
NMR spectrometer equipped with a triple-resonance cryogenic
probe and z-field gradients. Samples were prepared in a buffer
containing 25 mM HEPES, 50 mM NaCl and 500 lM TCEP (pH 7.0)
with 10% D2O (v/v) using DSS as an internal reference and imida-
zole to monitor pH. Backbone assignments of R0RBR parkin (Kumar
et al, 2015) and the pUbl domain (Aguirre et al, 2017) were
completed using standard triple-resonance methods as previously
reported. 1H–15N HSQC spectra were collected in TROSY mode
(Pervushin et al, 1997) to follow amide backbone chemical shift
perturbations. 1H–13C HMQC spectra (Tugarinov et al, 2004) were
collected to monitor chemical shifts of Ub side chain methyl groups.
1H–15N TROSY spectra were collected using different combinations
of 2H,13C,15N-labelled and 2H,15N-labelled R0RBR:pUb or R0RBR
with 2H,13C,15N or 2H,15N-labelled pUbl, Ub, UbcH7 or UbcH7-Ub.
For the 15N-labelled pUbl binding experiments, 1H–15N HSQC exper-
iments were collected to monitor pUbl chemical shift changes with
addition of equimolar amounts of unlabelled R0RBR:pUb and
UbcH7-Ub. Chemical shift perturbation measurements for amide
backbone resonances were calculated using Dd = ((DdH)2 + (DdN/
5)2)0.5 and for side chain methyl groups using Dd = ((DdH)2 +
(DdC/3.3)2)0.5. All data were processed using 60°-shifted cosine
bell-weighting functions using NMRPipe and NMRDraw (Delaglio
et al, 1995) and were analysed using NMRViewJ (Johnson &
Blevins, 1994).
Ubiquitin~Vinyl sulphone reactions
Individually purified proteins were acquired as described above.
The final concentration of each component was 10 lM in a final
volume of 45 ll [R0RBR and RING2(Rcat)] or 55 ll (parkin) in
50 mM HEPES and 50 mM NaCl (pH 8.0). Time started when the
UbVS (Boston Biochem) was added to the reaction at 37°C. 10 ll
was removed at each time point, and the reaction was quenched
with 3× SDS sample buffer. 16.5% SDS–PAGE gels were run and
stained with Coomassie Blue. Gels were imaged on a Bio-Rad
ChemiDoc XRS+. Band intensities of parkin-Ub (R0RBR-Ub),
parkin (R0RBR) and UbVS/pUb/pUbl were measured using
ImageJ software (Schneider et al, 2012). The per cent contribution
per band was calculated from the normalized intensity in each
lane.
Ubiquitination assays
These assays were monitored by fluorescence using Ub containing
an N-terminal cysteine residue linked to DyLight 800 Maleimide
(Ub800; Thermo Fisher Scientific) as previously described (Kumar
et al, 2015; Aguirre et al, 2018). All reactions were performed at
37°C and contained purified 1 lM wild type or substituted parkin,
0.5 lM UbcH7, 0.1 lM Uba1, 4 lM Ub and 0.5 lM Ub800 in 5 mM
MgATP, 50 mM HEPES (pH 7.5). pUb was added to 0.5 lM when
needed. To induce in situ phosphorylation, 0.01 lM of purified
GST-PINK1 was added to the parkin/pUb/ATP samples 30 min
before initiating ubiquitination. The ubiquitination reactions were
quenched with 3×SDS sample buffer and 1 M DTT. 4–12% Bis-Tris
gradient gels (Thermo Fisher Scientific) were used with MES
running buffer (250 mM MES, 250 mM Tris, 0.5% SDS and 5 mM
EDTA, pH 7.3). Fluorescence intensity at 700 and 800 nm was
measured using an Odyssey Imaging System (LI-COR).
HA-Miro1 ubiquitination reactions were performed at 30°C for
10 min in a buffer containing 50 mM Tris (pH 7.5), 100 mM NaCl,
5 mM MgCl2, 1 mM TCEP and 5% (v/v) glycerol. Reactions
contained 25 nm E1, 250 nM UbcH7, 250 nM pParkin, 10 lM Ub
(wild type or mutant), 5 lM HA-Miro1 and 5 mM ATP in final reac-
tion volume of 10 ll. Non-activatable pUb-6His (2.5 lM) was used
as an allosteric activator where indicated. Reactions were termi-
nated using NuPAGE LDS Sample Buffer (Invitrogen), resolved on
4–12% Bis-Tris gradient gels (Thermo Fisher Scientific) and trans-
ferred onto nitrocellulose membranes using iBlot Gel Transfer
Device (Invitrogen). Membranes were subjected to immunoblotting
using anti-HA mouse monoclonal primary antibody (901515, Bio
Legend, 1/5,000 dilution) and fluorescent-labelled secondary anti-
body (926-32213, Li-COR, 1/10,000 dilution). Blots were visualized
using Li-COR Odyssey Infrared Imaging System.
Parkin ubiquitin loading
Reactions monitoring pParkin-ubiquitin oxyester formation were
performed at 30°C for 60 min in a buffer containing 50 mM Tris
(pH 7.5), 100 mM NaCl, 5 mM MgCl2, 1 mM TCEP and 5%
(v/v) glycerol. Reactions contained 100 nM E1, 2.5 lM UbcH7,
2.5 lM pParkinC431S+H433A, 10 lM Ub (wild type or mutant) and
5 mM ATP in final reaction volume of 10 ll. Non-activatable
pUb-6His (2.5 lM) was included as an allosteric activator where
indicated. Reactions were stopped using NuPAGE LDS Sample
Buffer (Invitrogen) that contained reducing agents and boiled for
5 min. The samples were resolved on 4–12% Bis-Tris gradient
gels (Thermo Fisher Scientific) and analysed by Coomassie
staining.
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Hydrogen–deuterium exchange mass spectrometry
Deuteration of proteins occurred at 20  1°C in 90% D2O and 10%
H2O with 50 mM HEPES, 100 mM NaCl and 250 lM TCEP at pH
7.0. Parkin and pParkin:pUb sample concentrations were 1 lM.
UbcH7-Ub conjugate and pParkin:pUb concentrations were both
10 lM and were diluted to 1 lM in the above H2O buffer at pH 2.3.
100-ll aliquots were removed at time points between 15 s and
10 min following deuteration. Aliquots were quenched with ice-
chilled 10% HCl in H2O to reach a pH of 2.3 and then flash-frozen
in liquid nitrogen. Zero time point (m0) controls were created by
adding ice-chilled D2O to an ice-chilled protein sample under
quench conditions (pH 2.3) and flash-frozen. Fully exchanged
controls (m100) were also created by exposing the proteins to D2O at
pH 2.3 and heated to 70°C with a water bath for 8 h. These samples
were then flash-frozen in liquid nitrogen. Aliquots were thawed to
approximately 0°C and injected into a Waters HDX nanoACQUITY
HPLC system. Online digestion of the proteins was performed with a
POROS pepsin column at 15°C. The resulting peptides were trapped
and analysed on a Waters BEH C18 column at 0°C using a water/
acetonitrile with 0.1% formic acid gradient at 40 ll/min. The
peptide masses were measured using a Waters Synapt G2 Q-TOF
mass spectrometer. Peptides were identified through MS/MS. The
resulting peptides were analysed with Waters DynamX 3.0. Deutera-
tion is expressed here as per cent deuteration uptake where mt is
the centroid mass at time t and m0 and m100 are described above
according to the following equation:
%D uptake ¼ mt m0
m100 m0  100
Model determinations for UbcH7-Ub binding to R0RBR:pUb
Interacting residues were identified from NMR experiments (de-
scribed above) and defined as those amides that shifted greater than
the average + one standard deviation and residues that broadened/
shifted and could not be identified in the bound state (Fig EV2 and
Appendix Fig S3). These residues were filtered for those that had
> 20% side chain accessible surface area in each starting set of coor-
dinates (below). Passive residues were defined according to the
HADDOCK protocol (Dominguez et al, 2003; Bonvin et al, 2018) as
residues that neighboured active residues having > 20% side chain
accessible surface area and had chemical shift changes greater than
average. This approach led to a set of ambiguous restraints between
UbcH7 (K9, A59, E60, F63, K64, E93, N94, K96, A98) and R0RBR
parkin (T242, L266, T270, Q276, A291, G292, Q389-D394, R396)
and between Ub (F4, T7-G10, I11, E34, I36, V70, L71, L73, G75,
G76) and R0RBR parkin (Q276, V330, L331, R366, A379-S384,G385,
T386).
The UbcH7-Ub conjugate was docked to R0RBR:pUb using
HADDOCK (Dominguez et al, 2003) using the residues described
above. Starting coordinates from the crystal structure of pUb:
UblR0RBR (PDB code 5N2W) were used following removal of the
Ubl domain and adjoining linker coordinates (residues 1–83).
Several linker sections absent in crystal structures of parkin were
incorporated using the Modeller (Eswar et al, 2006) plug-in for
UCSF Chimera (Pettersen et al, 2004). The tether (387–405) that
partly occludes the RING1 binding site in the starting coordinates
was allowed to move. Coordinates for ubiquitin (PDB code 1UBQ;
Vijay-Kumar et al, 1987) and UbcH7 (PDB code 4Q5E; Grishin et al,
2014) were used to sequentially dock the UbcH7 and Ub moieties
untethered according to restraints and using a single unambiguous
restraint between the C-terminal G76 of ubiquitin and the catalytic
C86K of UbcH7 to create the UbcH7-Ub conjugate in the complex.
Upper distance limits of 4.0 A˚ were set for ambiguous distance
restraints, while the unambiguous distance restraint was set to
6.8 A˚. Standard HADDOCK parameters were used except inter_rigid
(0.1) which was set to allow tighter packing of the proteins, and the
unambiguous force constant was set fivefold higher compared to
those used the ambiguous constants. A total of 1,000 initial
complexes were calculated, and the best 100 structures were water-
refined.
Data availability
Coordinates for models of the UbcH7-Ub conjugate bound to
R0RBR:pUb reported here have been deposited to the Protein Data
Bank under accession number 6N13.
Expanded View for this article is available online.
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